Advanced Atherosclerosis in Predialysis Patients with Chronic Renal Failure
Overview
Authors
Affiliations
Background: Atherosclerosis is advanced in hemodialysis patients as shown by increased intima-media thickness of carotid arteries (CA-IMT), although it is not established whether the advanced atherosclerosis results from hemodialysis treatment or from chronic renal failure. The purpose of this study was to evaluate the effects of hemodialysis and renal failure on CA-IMT in patients with chronic renal failure.
Methods: CA-IMT was measured by high-resolution B-mode ultrasonography in 110 patients with chronic renal failure before starting dialysis (CRF group), and compared with CA-IMT of 345 hemodialysis patients (HD group) and 302 healthy control subjects. They were all nondiabetic and the three groups were comparable in age and gender.
Results: As compared with the healthy control subjects, the CRF and HD groups had greater CA-IMTs, whereas CA-IMTs of the CRF and HD groups were not statistically different. There was no significant correlation between duration of hemodialysis and CA-IMT in the HD group. Multiple regression analysis in the total subjects indicated that presence of renal failure, but not being treated with hemodialysis, was a significant factor associated with increased CA-IMT independent of age, gender, blood pressure, smoking, high-density lipoprotein (HDL) and non-HDL cholesterol levels.
Conclusions: These results demonstrate that thickening of arterial wall is present in patients with chronic renal failure before starting hemodialysis treatment, and support the concept that advanced atherosclerosis in hemodialysis patients is due not to hemodialysis treatment, but to renal failure and/or metabolic abnormalities secondary to renal failure.
K P, A A, M S, Prasad R Cureus. 2024; 16(5):e60308.
PMID: 38883001 PMC: 11177249. DOI: 10.7759/cureus.60308.
Kumagai G, Wada K, Asari T, Nitobe Y, Kinoshita H, Kushikata T Eur Spine J. 2023; 32(10):3352-3359.
PMID: 37326838 DOI: 10.1007/s00586-023-07823-0.
Significance of Levocarnitine Treatment in Dialysis Patients.
Takashima H, Maruyama T, Abe M Nutrients. 2021; 13(4).
PMID: 33917145 PMC: 8067828. DOI: 10.3390/nu13041219.
Beddhu S, Boucher R, Sun J, Balu N, Chonchol M, Navaneethan S BMC Nephrol. 2021; 22(1):69.
PMID: 33627066 PMC: 7905597. DOI: 10.1186/s12882-021-02260-x.
Insulin Resistance is Associated with Subclinical Vascular Injury in Patients with a Kidney Disease.
Adeva-Andany M, Fernandez-Fernandez C, Adeva-Contreras L, Carneiro-Freire N, Dominguez-Montero A, Mourino-Bayolo D Curr Cardiol Rev. 2020; 17(5):e160721189014.
PMID: 33305710 PMC: 8950454. DOI: 10.2174/1573403X16999201210200012.